In November 2012, MorphoSys announced a collaboration with Lanthio Pharma, a privately held Dutch biopharmaceutical company focused on discovering and developing lanthipeptides. MorphoSys also made an equity investment in Lanthio Pharma as part of the company’s Series A financing round. Lanthipeptides comprise a novel class of therapeutics with high target selectivity and improved drug-like properties. Lanthio Pharma's technology LanthioPep can be used to identify peptides which are selective for a specific disease target and to stabilize them in their optimal structural conformation for receptor binding.
MorphoSys and Lanthio Pharma will jointly apply their respective technologies to establish high-quality and diverse lanthipeptide-based libraries. MorphoSys receives preferred rights to exclusively license the LanthioPep technology for drug discovery.
In October 2014, MorphoSys exercised an option within the ongoing agreement and acquired Lanthio Pharma's lanthipeptide technology, which will be used for drug discovery by MorphoSys. By exercising the option, MorphoSys takes over the lanthipeptide technology and all related intellectual property. Lanthio Pharma will continue to focus on building its portfolio of selected lanthipeptide drugs and will participate financially in MorphoSys's exploitation of the technology.